HyperAcute Melanoma (dorgenmeltucel-L) / Lumos Pharma - LARVOL DELTA

NLG-0304: Immunotherapy Study for Patients With Stage IV Melanoma (clinicaltrials.gov) - P2b | N=47 | Terminated | Sponsor: NewLink Genetics Corporation | Active, not recruiting ➔ Terminated; Withdrawal of IND

Checkpoint inhibition • Metastases • Trial termination • Immune Modulation • Melanoma • Oncology • Solid Tumor

Immunotherapy Study for Patients With Stage IV Melanoma (clinicaltrials.gov) - P2b; N=47; Active, not recruiting; Sponsor: NewLink Genetics Corporation; Recruiting ➔ Active, not recruiting; Phase classification: P2 ➔ P2b

Enrollment closed • Phase classification